Lineage Cell Therapeutics, Inc. Proceeds from Sale of Productive Assets
Lineage Cell Therapeutics, Inc. (LCTX) reported Proceeds from Sale of Productive Assets of $14.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2022-03-10
- Lineage Cell Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2021 was $14.00K, a 39.13% decline from fiscal 2020.
- Lineage Cell Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2020 was $23.00K, a 71.95% decline from fiscal 2019.
- Lineage Cell Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2019 was $82.00K.
- Lineage Cell Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2017 was $200.00K.
| Period end | Proceeds from Sale of Productive Assets 12 month |
|---|---|
| 2021-12-31 | $14.00K 10-K · filed 2022-03-10 |
| 2020-12-31 | $23.00K 10-K · filed 2022-03-10 |
| 2019-12-31 | $82.00K 10-K · filed 2021-03-11 |
| 2017-12-31 | $200.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |